William Blair analyst Myles Minter has reiterated their bullish stance on ALNY stock, giving a Buy rating yesterday.
Myles Minter has given his Buy rating due to a combination of factors surrounding Alnylam Pharma’s recent developments. The FDA’s approval of Qfitlia, an RNAi therapeutic for hemophilia A and B, marks a significant milestone for the company. This approval not only adds another revenue stream but also highlights the clinical de-risking of Alnylam’s pipeline, making it a compelling growth story for 2025.
Qfitlia’s efficacy was demonstrated in the Phase III ATLAS study, where it significantly reduced bleeding rates compared to traditional treatments. Despite the presence of a black box warning for thromboembolic events, the overall safety profile showed fewer adverse events compared to on-demand clotting factor concentrates. The innovative approach of reducing antithrombin to increase thrombin levels offers a promising alternative to costly and complex factor replacement therapies, especially for patients with inhibitors. These factors contribute to Minter’s optimistic outlook on Alnylam’s stock.
In another report released yesterday, Bernstein also reiterated a Buy rating on the stock with a $305.00 price target.